• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

伊维菌素、抗病毒特性和 COVID-19：一种可能的新作用机制。

Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.

机构信息

Department of Prevention, Local Health Authority of Lecce (ASL Lecce), Lecce, Italy.

Italian Society of Environmental Medicine (SIMA), Milan, Italy.

出版信息

Naunyn Schmiedebergs Arch Pharmacol. 2020 Jul;393(7):1153-1156. doi: 10.1007/s00210-020-01902-5. Epub 2020 May 27.

DOI:10.1007/s00210-020-01902-5
PMID:32462282
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7251046/
Abstract

Ivermectin is an antiparasitic drug that has shown also an effective pharmacological activity towards various infective agents, including viruses. This paper proposes an alternative mechanism of action for this drug that makes it capable of having an antiviral action, also against the novel coronavirus, in addition to the processes already reported in literature.

摘要

伊维菌素是一种抗寄生虫药物，它对包括病毒在内的各种感染性病原体也表现出有效的药理活性。本文提出了这种药物的另一种作用机制，使其能够具有抗病毒作用，不仅针对新型冠状病毒，还针对文献中已经报道的过程。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53ff/7251046/33b96abc7571/210_2020_1902_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53ff/7251046/03180794623e/210_2020_1902_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53ff/7251046/33b96abc7571/210_2020_1902_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53ff/7251046/03180794623e/210_2020_1902_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53ff/7251046/33b96abc7571/210_2020_1902_Fig2_HTML.jpg

相似文献

1
Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.伊维菌素、抗病毒特性和 COVID-19：一种可能的新作用机制。
Naunyn Schmiedebergs Arch Pharmacol. 2020 Jul;393(7):1153-1156. doi: 10.1007/s00210-020-01902-5. Epub 2020 May 27.
2
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.美国食品药品监督管理局批准的药物伊维菌素可抑制 SARS-CoV-2 的体外复制。
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
3
Metabolomics to Predict Antiviral Drug Efficacy in COVID-19.代谢组学预测COVID-19中抗病毒药物疗效
Am J Respir Cell Mol Biol. 2020 Sep;63(3):396-398. doi: 10.1165/rcmb.2020-0206LE.
4
Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.伊维菌素可能是一种对晚期新冠肺炎有临床实用价值的抗炎药。
Open Heart. 2020 Sep;7(2). doi: 10.1136/openhrt-2020-001350.
5
Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?伊维菌素作为一种广谱宿主导向抗病毒药物：真有那么神？
Cells. 2020 Sep 15;9(9):2100. doi: 10.3390/cells9092100.
6
Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing.开发一种最小生理基于药代动力学模型，以模拟新冠肺炎药物再利用中经口给予伊维菌素后人体肺部的暴露情况。
J Pharm Sci. 2020 Dec;109(12):3574-3578. doi: 10.1016/j.xphs.2020.08.024. Epub 2020 Sep 4.
7
Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach.利用全面的药物再利用和分子对接方法预测 SARS-CoV-2 的 RNA 依赖性 RNA 聚合酶的潜在抑制剂。
Int J Biol Macromol. 2020 Nov 15;163:1787-1797. doi: 10.1016/j.ijbiomac.2020.09.098. Epub 2020 Sep 17.
8
Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein.阿比多尔：通过阻断刺突糖蛋白三聚化治疗 SARS-CoV-2 的一种有潜力的抗病毒药物。
Int J Antimicrob Agents. 2020 Aug;56(2):105998. doi: 10.1016/j.ijantimicag.2020.105998. Epub 2020 Apr 28.
9
Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy.将突变灾难视为一种潜在的新冠病毒治疗策略。
Heredity (Edinb). 2020 May;124(5):619-620. doi: 10.1038/s41437-020-0314-z. Epub 2020 Apr 6.
10
Lung tissue distribution of drugs as a key factor for COVID-19 treatment.药物在肺组织中的分布作为COVID-19治疗的关键因素。
Br J Pharmacol. 2020 Nov;177(21):4995-4996. doi: 10.1111/bph.15102. Epub 2020 Jun 9.

引用本文的文献

1
Utility of sustainable ratio derivative spectrophotometry for the concurrent assay of synergistic repurposed drugs for COVID-19 infections; Insilico pharmacokinetics proof.可持续比率导数分光光度法用于同时测定 COVID-19 感染协同性重新利用药物的效用；计算机模拟药代动力学验证。
BMC Chem. 2024 Mar 7;18(1):50. doi: 10.1186/s13065-024-01147-w.
2
Results of a systematic review and meta-analysis of early studies on ivermectin in SARS-CoV-2 infection.系统评价和荟萃分析早期伊维菌素治疗 SARS-CoV-2 感染的研究结果。
Geroscience. 2023 Aug;45(4):2179-2193. doi: 10.1007/s11357-023-00756-y. Epub 2023 Mar 7.
3
Electrostatic Surface Potential as a Key Parameter in Virus Transmission and Evolution: How to Manage Future Virus Pandemics in the Post-COVID-19 Era.

本文引用的文献

1
The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug.多靶点药物伊维菌素：从抗寄生虫药到重新定位的抗癌药。
Am J Cancer Res. 2018 Feb 1;8(2):317-331. eCollection 2018.
2
Streptomyces avermectinius sp. nov., an avermectin-producing strain.阿维链霉菌新种，一种产阿维菌素的菌株。
Int J Syst Evol Microbiol. 2002 Nov;52(Pt 6):2163-2168. doi: 10.1099/00207713-52-6-2163.
静电表面电势作为病毒传播和进化的关键参数：在后 COVID-19 时代如何管理未来的病毒大流行。
Viruses. 2023 Jan 19;15(2):284. doi: 10.3390/v15020284.
4
A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective?基于细胞和分子生物学的伊维菌素治疗 COVID-19 的更新：它是否有效？
Inflammopharmacology. 2023 Feb;31(1):21-35. doi: 10.1007/s10787-022-01129-1. Epub 2023 Jan 7.
5
Bibliometric development of Naunyn-Schmiedeberg's Archives of Pharmacology.《瑙文-施密德贝格药理学档案的文献计量学发展》。
Naunyn Schmiedebergs Arch Pharmacol. 2023 Jan;396(1):43-61. doi: 10.1007/s00210-022-02307-2. Epub 2022 Oct 25.
6
Microbiome-Based Hypothesis on Ivermectin's Mechanism in COVID-19: Ivermectin Feeds Bifidobacteria to Boost Immunity.基于微生物群的伊维菌素在COVID-19中作用机制的假说：伊维菌素通过滋养双歧杆菌来增强免疫力。
Front Microbiol. 2022 Jul 11;13:952321. doi: 10.3389/fmicb.2022.952321. eCollection 2022.
7
The Effect of Ivermectin on Cases of COVID-19.伊维菌素对 COVID-19 病例的影响。
Cardiovasc Revasc Med. 2022 Nov;44:98-100. doi: 10.1016/j.carrev.2022.06.004. Epub 2022 Jun 17.
8
Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review.伊维菌素和强力霉素联合治疗可有效缓解疫苗接种运动期间 COVID-19 感染的细胞因子风暴：叙述性评论。
J Infect Public Health. 2022 May;15(5):566-572. doi: 10.1016/j.jiph.2022.03.014. Epub 2022 Mar 30.
9
Can anti-parasitic drugs help control COVID-19?抗寄生虫药物能帮助控制新冠病毒吗？
Future Virol. 2022 Mar. doi: 10.2217/fvl-2021-0160. Epub 2022 Mar 18.
10
Therapeutics for COVID-19 and post COVID-19 complications: An update.新型冠状病毒肺炎及其后遗症的治疗：最新进展
Curr Res Pharmacol Drug Discov. 2022;3:100086. doi: 10.1016/j.crphar.2022.100086. Epub 2022 Feb 4.